Biochemical and neuroendocrine approaches to a malignant syndrome of neuroleptics.
A 20 year old patient who has been hospitalized for depressive schizoidia is treated by nomifensine (75 mg/d) plus pimozide (4 mg/d). Four days later, he shows a typical neuroleptic malignant syndrome (Syndrome malin de Delay et Deniker). The biological explorations show that inflammatory blood tests are increased, hepatic tests are disturbed and the pituitary tests suggest a hypothalamic disturbance of the balance between NE and DA (reduced STH, FHS and LH) with a relative NE predominance, but also an increase of DA (increased HVA in CSF. A pathogenic interaction between nomifensine, an antidepressant inhibiting the reuptake of NE and DA, and pimozide, a neuroleptic blocking dopaminergic postsynaptical receptors is to be considered.
D000328:Adult; D001342:Autonomic Nervous System Diseases / Q000139:chemically induced*; D001480:Basal Ganglia Diseases / Q000139:chemically induced*; D005334:Fever / Q000139:chemically induced*; D006801:Humans; D007546:Isoquinolines / Q000009:adverse effects*; D008297:Male; D009627:Nomifensine / Q000009:adverse effects*; D010868:Pimozide / Q000009:adverse effects*; D012559:Schizophrenia / Q000188:drug therapy*; D013577:Syndrome
D007546:Isoquinolines; D010868:Pimozide; D009627:Nomifensine